Drug intelligence / Profile preview

P1

Development stage: Preclinical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

**P1** is an experimental colon-targeted theranostic prodrug in which 5-aminosalicylic acid is covalently linked to the fluorescent reporter 7-amino-4-methylcoumarin through an azobond. Colonic azoreductase activity reduces the azo linkage, releasing 5-aminosalicylic acid and restoring coumarin fluorescence. The molecule was investigated in polymeric micelles to improve solubility and preferential delivery to inflamed colonic tissue in a mouse model of ulcerative colitis. P1 is a research-stage, single-molecule prodrug rather than an approved pharmaceutical product. ([sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S0039914024016564))

Targets

AzR (Bacterial azoreductase)

Beyond the preview

Go deeper on P1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P1.

Explore the full profile